Continuous function of 80 primary renal allografts for 30–47 years with maintenance prednisone and azathioprine/mycophenolate mofetil therapy: A clinical mosaic of long‐term successes. Issue 1 (27th November 2020)
- Record Type:
- Journal Article
- Title:
- Continuous function of 80 primary renal allografts for 30–47 years with maintenance prednisone and azathioprine/mycophenolate mofetil therapy: A clinical mosaic of long‐term successes. Issue 1 (27th November 2020)
- Main Title:
- Continuous function of 80 primary renal allografts for 30–47 years with maintenance prednisone and azathioprine/mycophenolate mofetil therapy: A clinical mosaic of long‐term successes
- Authors:
- Braun, William E.
Herlitz, Leal
Li, Jianbo
Schold, Jesse
Poggio, Emilio
Stephany, Brian
Fatica, Richard
Nally, Joseph
Brown, Kathleen
Fairchild, Robert
Baldwin, William
Goldfarb, David
Kiser, William
Augustine, Joshua
Avery, Robin
Tomford, J. Walton
Nakamoto, Satoru - Abstract:
- Abstract: Eighty primary renal allograft recipients, 61 living‐related and 19 deceased donor, transplanted from 1963 through 1984 had continuous graft function for 30–47 years. They were treated with three different early immunosuppression programs (1963–1970: thymectomy, splenectomy, high oral prednisone; 1971–1979: divided‐dose intravenous methylprednisolone; and 1980–1984: antilymphocyte globulin) each with maintenance prednisone and azathioprine, and no calcineurin inhibitor. Long‐term treatment often included the anti‐platelet medication, dipyridamole. Although both recipient and donor ages were young (27.2 ± 9.5 and 33.1 ± 12.0 years, respectively), six recipients with a parent donor had >40‐year success. At 35 years, death‐censored graft survival was 85.3% and death with a functioning graft 84.2%; overall graft survival was 69.5% (Kaplan–Meier estimate). Biopsy‐documented early acute cellular and highly probable antibody‐mediated rejections were reversed with divided‐dose intravenous methylprednisolone. Complications are detailed in an integrated timeline. Hypogammaglobulinemia identified after 20 years doubled the infection rate. An association between a monoclonal gammopathy of undetermined significance and non‐plasma‐cell malignancies was identified. Twenty‐seven azathioprine‐treated patients tested after 37 years had extremely low levels of T1/T2 B lymphocytes representing a "low immunosuppression state of allograft acceptance (LISAA)". The lifetime achievementsAbstract: Eighty primary renal allograft recipients, 61 living‐related and 19 deceased donor, transplanted from 1963 through 1984 had continuous graft function for 30–47 years. They were treated with three different early immunosuppression programs (1963–1970: thymectomy, splenectomy, high oral prednisone; 1971–1979: divided‐dose intravenous methylprednisolone; and 1980–1984: antilymphocyte globulin) each with maintenance prednisone and azathioprine, and no calcineurin inhibitor. Long‐term treatment often included the anti‐platelet medication, dipyridamole. Although both recipient and donor ages were young (27.2 ± 9.5 and 33.1 ± 12.0 years, respectively), six recipients with a parent donor had >40‐year success. At 35 years, death‐censored graft survival was 85.3% and death with a functioning graft 84.2%; overall graft survival was 69.5% (Kaplan–Meier estimate). Biopsy‐documented early acute cellular and highly probable antibody‐mediated rejections were reversed with divided‐dose intravenous methylprednisolone. Complications are detailed in an integrated timeline. Hypogammaglobulinemia identified after 20 years doubled the infection rate. An association between a monoclonal gammopathy of undetermined significance and non‐plasma‐cell malignancies was identified. Twenty‐seven azathioprine‐treated patients tested after 37 years had extremely low levels of T1/T2 B lymphocytes representing a "low immunosuppression state of allograft acceptance (LISAA)". The lifetime achievements of these patients following a single renal allograft and low‐dose maintenance immunosuppression are remarkable. Their success evolved as a clinical mosaic. … (more)
- Is Part Of:
- Clinical transplantation. Volume 35:Issue 1(2021)
- Journal:
- Clinical transplantation
- Issue:
- Volume 35:Issue 1(2021)
- Issue Display:
- Volume 35, Issue 1 (2021)
- Year:
- 2021
- Volume:
- 35
- Issue:
- 1
- Issue Sort Value:
- 2021-0035-0001-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2020-11-27
- Subjects:
- azathioprine -- B cell biology -- biopsy -- complication -- immunosuppressant -- malignancy -- medical/metabolic
Transplantation of organs, tissues, etc -- Periodicals
617.95 - Journal URLs:
- http://www.blackwell-synergy.com/member/institutions/issuelist.asp?journal=ctr ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/ctr.14131 ↗
- Languages:
- English
- ISSNs:
- 0902-0063
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3286.399780
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 22418.xml